RXRX — Recursion Pharmaceuticals Balance Sheet
0.000.00%
- $2.05bn
- $1.75bn
- $44.58m
Annual balance sheet for Recursion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 69.9 | 262 | 517 | 550 | 392 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.151 | 0.156 | 9.09 | 2.75 | 3.09 |
Total Other Current Assets | |||||
Total Current Assets | 76.4 | 266 | 535 | 570 | 438 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 24.4 | 26 | 64.7 | 121 | 120 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 101 | 299 | 610 | 701 | 654 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.68 | 23.1 | 46.7 | 100 | 93.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 24.6 | 56.6 | 67.4 | 215 | 190 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 76.8 | 242 | 543 | 486 | 463 |
Total Liabilities & Shareholders' Equity | 101 | 299 | 610 | 701 | 654 |
Total Common Shares Outstanding |